For emerging biotech companies, choosing the right CDMO (Contract Development and Manufacturing Organization) is one of the most pivotal decisions in the path to commercialization. The right partner doesn’t just manufacture your drug product—they help navigate complex regulatory hurdles, scale production efficiently, and support your journey from the lab to the market.
As clinical candidates move closer to commercialization, here’s what biotechs should prioritize when evaluating CDMO partners.
1. Proven Experience with Late-Stage and Commercial-Scale Projects
While early-phase formulation support is important, your CDMO should also demonstrate a strong track record in scaling to commercial volumes. Look for a partner with experience in commercial launches and managing tech transfer from pilot scale to full-scale production. Facilities, batch size flexibility, and production planning capabilities all matter here.
Mikart supports a full range of clinical through commercial-scale manufacturing, providing turnkey solutions tailored to each phase of development.
2. Robust Regulatory Knowledge and Compliance
As you prepare for IND, NDA, or ANDA submissions, your CDMO must operate in full compliance with cGMP standards and have familiarity with both FDA and global regulatory expectations. This includes documentation practices, audit readiness, and an understanding of complex regulatory pathways.
Ask potential partners:
- Have they supported successful regulatory filings?
- Are they prepared for pre-approval inspections (PAIs)?
- What is their audit history?
Mikart’s facilities are routinely audited by the FDA and global partners, with a strong compliance track record and extensive regulatory support.
3. Integrated Development Services for Faster Timelines
A truly valuable CDMO partner should offer integrated development and manufacturing services—including analytical testing, formulation, stability, packaging, and tech transfer—under one roof. This integration reduces delays, ensures knowledge continuity, and streamlines development timelines.
Mikart offers a cohesive, end-to-end development platform to simplify project coordination and accelerate time-to-market.
4. Technical Expertise in Your Dosage Form
Not all CDMOs are created equal. If your product is a liquid suspension, solid oral dosage, or requires specialized nanoformulation, you need a partner who not only understands your dosage form but has optimized it repeatedly.
Mikart specializes in complex solid and liquid oral formulations—including poorly soluble APIs and pediatric-friendly formats—supported by advanced technologies like nano-transformer systems.
5. Supply Chain & Packaging Capabilities
Beyond formulation and manufacturing, your CDMO should have packaging infrastructure to support clinical and commercial distribution. This includes blister, bottle, and unit-dose packaging as well as serialization and labeling capabilities to meet market demands.
Mikart’s in-house packaging lines support a wide range of formats, ensuring supply chain continuity from batch release to delivery.
6. Transparent Communication & Project Management
Smooth communication, proactive updates, and knowledgeable project managers are key to preventing costly delays and misunderstandings. Ask about:
- Project management tools used
- Frequency of updates and milestones
- Escalation procedures if issues arise
Mikart’s collaborative approach and experienced PM team keep biotech partners informed, involved, and confident at every stage.
7. Flexibility and Long-Term Partnership Potential
Biotechs need CDMOs who understand the unpredictable nature of drug development. Can your partner accommodate shifting timelines, batch sizes, or formulation tweaks? More importantly, do they invest in your long-term success?
Mikart values long-term partnerships and adapts to the evolving needs of each client, offering scalable support and strategic guidance.
Conclusion: Build With the Future in Mind
As you advance toward commercialization, partnering with the right CDMO ensures your product is in expert hands—prepared for regulatory approval, optimized for scale, and aligned with your business goals.
Mikart is proud to support biotech innovators with flexible, full-service CDMO solutions. Whether you’re developing a new drug for a rare disease or reformulating for improved bioavailability, our team is here to help you succeed.
Ready to take the next step? Reach out to our Business Development team at BizDev@mikart.com or contact us here to start the conversation.